| abstract |
The present invention provides an efavirenz tablet formulation which, when administered as a single dose to a subject, provides a mean maximum plasma concentration (Cmax) of about 4µM to about 14µM, a mean time of maximum plasma concentration (Tmax) of about 2 hours to about 5 hours, and a mean area under the plasma concentration versus time curve from time zero to time infinity (AUC) of about 190µM/hour to about 470µM/hour. |